BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters

24 Jun

BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

June 24 (Reuters) - Nektar Therapeutics NKTR.O:

REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS
NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16
NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS
NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY
NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025

Source text: ID:nPn82vpC8a

Further company coverage: NKTR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2545812572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545812572\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545812572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545812572","market":"fut","top_or_hot":-1,"title":"BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis</title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NKTR.O</span>:</p><ul><li><p>REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS</p></li><li><p>NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS</p></li><li><p>NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16</p></li><li><p>NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS</p></li><li><p>NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY</p></li><li><p>NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025</p></li></ul><p>Source text: <span>ID:nPn82vpC8a</span></p><p>Further company coverage: <span>NKTR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis</title></head><body><p><span>June 24 (Reuters)</span><span> - </span>Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NKTR.O</span>:</p><ul><li><p>REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS</p></li><li><p>NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS</p></li><li><p>NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16</p></li><li><p>NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS</p></li><li><p>NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY</p></li><li><p>NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025</p></li></ul><p>Source text: <span>ID:nPn82vpC8a</span></p><p>Further company coverage: <span>NKTR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nTUA8BRMFQ:1","article_id":"2545812572","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545812572","pubTimestamp":1750765064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic DermatitisJune 24 (Reuters) - Nektar Therapeutics NKTR.O:REZOL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4007":"制药"},"translate_title":"BRIEF-REZOLVE-AD rezpegaldesleukin的2B期研究在中度至重度特应性皮炎患者中达到主要和关键次要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic DermatitisJune 24 (Reuters) - Nektar Therapeutics NKTR.O:REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISNEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTSNEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTSNEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDYNEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025Source text: ID:nPn82vpC8aFurther company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}